Vishal Kumar Vishwakarma

Vishal Kumar Vishwakarma

Auto-generated profile, based on publicly available information

Vishal Kumar Vishwakarma

Institute of Pharmacy, Deen Dayal Upadhyay Gorakhpur University, Uttar Pradesh, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
SSSadia Shah
Sadia Shah
VVVishal Kumar Vishwakarma
Vishal Kumar Vishwakarma
SASudheer Kumar Arava
Sudheer Kumar Arava
AMAsit Ranjan Mridha
Asit Ranjan Mridha
RYRaj Kumar Yadav
Raj Kumar Yadav
HYHarlokesh Narayan Yadav
Harlokesh Narayan Yadav

4 January 2019 in Drug Research
Verified
Journal Article
Closed access
PDF file
VVVishal Kumar Vishwakarma
Vishal Kumar Vishwakarma
PUPrabhat Kumar Upadhyay
Prabhat Kumar Upadhyay
HCHridaya Shanker Chaurasiya
Hridaya Shanker Chaurasiya
RSRitesh Kumar Srivasatav
Ritesh Kumar Srivasatav
TATarique Mahmood Ansari
Tarique Mahmood Ansari
VSVivek Srivastava
Vivek Srivastava
A study of potassium channels correlates the fundamentals of mechanistic pathways and various physiological functions. The knowledge of these pathways provides the background, how to determine unit cell functions and to affect cardio protection. ATP sensitive potassium channels adjust excitability of membrane and functions as per metabolic status of cell. A lot of energy consumption primarily occurred in skeletal muscles which also express high number of potassium channels. The increase in calcium release and high heat production is occurred due to loss of potassium channels. Such type of mediations determines metabolic changes and energy required in the dissipation. IPC reduces infarct size in anesthetized mice. In ischemic-reperfusion, pressure in left ventricle was watched while contractile power recovery did not happen. It was seen that elements of intact potassium channel are fundamental for Ischemic preconditioning (IPC). If more prominent is enactment of potassium channels and their cardiologic effects create high heart rate. All the more as of late, it has been suggested that mitochondrial ATP sensitive potassium channels are critical as closing stage effectors which trigger IPC as opposed to sarcolemmal potassium channels. Nevertheless, the importance of the potassium channels reconsidered in cardio-protection in present findings. These discoveries recommend that potassium channels in the adjusting ischemic-reperfusion damage in mice. The heart rate of the mouse occurred during ischemia; enhance watchful extrapolation applied to larger warm blooded animals.

17 September 2017 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
VVVk Vishwakarma
Vk Vishwakarma
AGA Goyal
A Goyal
JGJk Gupta
Jk Gupta
PUPk Upadhyay
Pk Upadhyay
HYHarlokesh Narayan Yadav
Harlokesh Narayan Yadav
Background: Nitric oxide (NO) is an effective mediator of ischemic preconditioning (IPC)-induced cardioprotection. Atrial natriuretic peptide (ANP) is downregulated after ovariectomy, which results in reduction in the level of NO. The present study deals with the investigation of the role of ANP in abrogated cardioprotective effect of IPC in the ovariectomized rat heart. Methods: Heart was isolated from ovariectomized rat and mounted on Langendorff’s apparatus, subjected to 30 min of ischemia and 120 min of reperfusion. IPC was given by four cycles of 5 min of ischemia and 5 min of reperfusion with Krebs–Henseleit solution. The myocardial infract size was estimated employing triphenyltetrazolium chloride stain, and coronary effluent was analyzed for creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) release to consider the degree of myocardial injury. The cardiac release of NO was estimated by measuring the level of nitrite in coronary effluent. Results: IPC-mediated cardioprotection was significantly attenuated in ovariectomized rat as compared to normal rat, which was restored by perfusion with ANP. However, this observed cardioprotection was significantly attenuated by perfusion with L-NAME, an endothelial nitric oxide synthase inhibitor, and Glibenclamide, a KATP channel blocker, alone or in combination noted in terms of increase in myocardial infract size, release of CK-MB and LDH, and also decrease in release of NO. Conclusion: Thus, it is suggested that ANP restores the attenuated cardioprotective effect of IPC in the ovariectomized rat heart which may be due to increase in the availability of NO and consequent increase activation of mitochondrial KATP channels.

18 February 2019 in Drug Research
Verified
Journal Article
Open access
PDF file
RSRitesh Kumar Srivastav
Ritesh Kumar Srivastav
TATarique Mahmood Ansari
Tarique Mahmood Ansari
MPMahesh Prasad
Mahesh Prasad
VVVishal Kumar Vishwakarma
Vishal Kumar Vishwakarma
PBParamdeep Bagga
Paramdeep Bagga
FAFarogh Ahsan
Farogh Ahsan
Caveolae have impressive morphological highlights of the cytomembrane of mammalian cells which involve in wide diversity of cellular functions involving signaling pathways and cholesterol hastening. Caveolin proteins possess a ‘scaffolding’ domain which for caveolin-1 and caveolin-3 appear to act a dominant role in signal regulation through caveolae. Caveolin-1 is treated to be protein in the cytomembrane entrapped with caveolae in endothelial cells and vascular smooth muscle cells which diminish nitric oxide (NO) by fill up the calcium/calmodulin (Ca2+/CaM) confining point of endothelial nitric oxide synthase (eNOS), decrease NO generation produce endothelial dysfunction and atherosclerotic injury development. It is a cholesterol-binding layer protein associated with cell cholesterol transport and also shows cardioprotective action through ischemic preconditioning (IPC) in diabetic and postmenopausal rat heart. Additionally it is ensnared in the procedures of tumorigenesis, prostate disease, and inflammation. The present study in the paper is to explore the structural functionalities of caveolins and their contributory role in CVS disorders and various other diseases.

25 May 2023 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
VVVishal Kumar Vishwakarma
Vishal Kumar Vishwakarma
SSSadia Shah
Sadia Shah
TKTajpreet Kaur
Tajpreet Kaur
ASAmrit Pal Singh
Amrit Pal Singh
SASudheer Kumar Arava
Sudheer Kumar Arava
HYHarlokesh Narayan Yadav
Harlokesh Narayan Yadav
Objective: Diabetic cardiomyopathy (DC) is one of the severe secondary complications of diabetes mellitus in humans. Vinpocetine is an alkaloid having pleiotropic pharmacological effects. The present study is designed to investigate the effect of vinpocetine in DC in rats. Methods: Rats were fed a high-fat diet for nine weeks along with single dose of streptozotocin after the second week to induce DC. The haemodynamic evaluation was performed to assess the functional status of rats using the Biopac system. Cardiac echocardiography, biochemical, oxidative stress parameters and inflammatory cytokine level were analysed in addition to haematoxylin–eosin and Masson’s trichome staining to study histological changes, cardiomyocyte diameter and fibrosis, respectively. Phosphodiesterase-1 (PDE-1), transforming growth factor-β (TGF-β) and p-Smad 2/3 expression in cardiac tissues were quantified using western blot/RT-PCR. Key finding: Vinpocetine treatment and its combination with enalapril decreased the glucose levels compared to diabetic rats. Vinpocetine improved the echocardiographic parameters and cardiac functional status of rats. Vinpocetine decreased the cardiac biochemical parameters, oxidative stress, inflammatory cytokine levels, cardiomyocyte diameter and fibrosis in rats. Interestingly, expressions of PDE-1, TGF-β and p-Smad 2/3 were ameliorated by vinpocetine alone and in combination with enalapril. Conclusions: Vinpocetine is a well-known inhibitor of PDE-1 and the protective effect of vinpocetine in DC is exerted by inhibition of PDE-1 and subsequent inhibition of the expression of TGF-β/Smad 2/3.

1 November 2021 in Current Reviews in Clinical and Experimental Pharmacology
Verified
Journal Article
Closed access
PDF file
ZAZia Abdullah
Zia Abdullah
AKArvind Kumar
Arvind Kumar
MKM. A. Khan
M. A. Khan
UKUma Kumar
Uma Kumar
SVSurabhi Vyas
Surabhi Vyas
NWNaveet Wig
Naveet Wig
Objective: The study was conducted to determine whether synthetic Disease-Modifying Anti Rheumatic Drugs (DMARDs) suppress the latency of Tuberculosis (TB) infection in Rheumatoid Arthritis (RA) patients along with other variables. Methods: This was done through Tuberculin Skin Test (TST) using purified protein derivative (PPD) in a cohort of RA patients. The TST was taken positive when induration post-PPD injection was ≥ 5mm and negative or anergic when it was <5mm. We included 100 patients (N = 100). Results: The prevalence of positive TST was 36%, while 64% presented a negative result. Negative TST was significantly associated with steroid usage (39.4%, 95% CI: 28.4%-51.4%). Anergic (TST negative) and non-anergic (TST positive) patients were separated into groups, and a new analysis was conducted with elaboration on DMARDs used. Conclusion: The use of steroids was associated with TST negativity, The same is not true with use of methotrexate or other DMARDs. Thus TST should be interpreted with caution, especially before starting biologicals.